European Journal of Clinical Pharmacology

, Volume 67, Issue 5, pp 535–536 | Cite as

Low persistence of anticholinergic drug use in Sweden

  • Love LinnérEmail author
  • Helena Schiöler
  • Eva Samuelsson
  • Ian Milsom
  • Fredrik Nilsson
Letter to the Editors


The frequency and severity of urge incontinence and overactive bladder in a population increase with advancing age [1, 2]. The initial treatment for patients seeking medical care for these symptoms is often bladder training. Subsequent treatment with anticholinergic agents may be initiated in the absence of a sufficient treatment effect by bladder training alone.

There is evidence that treatment with anticholinergics for urge incontinence provides beneficial effects on disease-specific quality of life [3]. However, these effects are small in many cases, and mild adverse effects are common. Only a proportion of patients are therefore satisfied with the effect of the treatment [4, 5].

The anticholinergic drugs provided in Sweden are oxybutynin (tablets, patches), tolterodine, solifenacin, darifenacin and fesoterodine. All products except oxybutynin (tablets) are originator products without generic competition and are more costly than the generic oxybutynin. During the last 10 years...


Adherence Rate Oxybutynin Urge Incontinence Tolterodine Anticholinergic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Mikael Hoffmann at NEPI, The Swedish Foundation for Pharmacoepidemiology


  1. 1.
    Hannestad YS, Rortveit G, Sandvik H, Hunskaar S (2000) A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of incontinence in the county of Nord-Trondelag. J Clin Epidemiol 53(11):1150–1157PubMedCrossRefGoogle Scholar
  2. 2.
    Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the epic study. Eur Urol 50(6):1306–1314, discussion 1314-1305PubMedCrossRefGoogle Scholar
  3. 3.
    Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J (2006) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev (Online) 4:CD003781Google Scholar
  4. 4.
    Kelleher CJ, Pleil AM, Reese PR, Burgess SM, Brodish PH (2004) How much is enough and who says so? Bjog 111(6):605–612PubMedGoogle Scholar
  5. 5.
    Pleil AM, Coyne KS, Reese PR, Jumadilova Z, Rovner ES, Kelleher CJ (2005) The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue—the BSW. Value Health 8[Suppl 1]:S25–S34PubMedCrossRefGoogle Scholar
  6. 6.
    Hay-Smith J, Herbison P, Ellis G, Morris A (2005) Cochrane Database Syst Rev(Online) 3:CD005429Google Scholar
  7. 7.
    Brostrom S, Hallas J (2009) Persistence of antimuscarinic drug use. Eur J Clin Pharmacol 65(3):309–314PubMedCrossRefGoogle Scholar
  8. 8.
    Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundstrom A, Westerholm B, Rosen M (2007) The new Swedish prescribed drug register—opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16(7):726–735PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Love Linnér
    • 1
    Email author
  • Helena Schiöler
    • 2
  • Eva Samuelsson
    • 3
  • Ian Milsom
    • 4
  • Fredrik Nilsson
    • 1
  1. 1.The Dental and Pharmaceutical Benefits AgencySolnaSweden
  2. 2.The National Board of Health and WelfareStockholmSweden
  3. 3.Department of Public Health and Clinical Medicine, Family Medicine, Umeå UniversityUmeåSweden
  4. 4.Department of Obstetrics & Gynecology, Institute of Clinical SciencesSahlgrenska Academy at Gothenburg UniversityGothenburgSweden

Personalised recommendations